Among PPF patients, treatment with BMS-986278 reduced the rate of decline in percent predicted forced vital capacity by 69% compared with placebo. The Food and Drug Administration (FDA) has granted ...

A new treatment possibility for pulmonary fibrosis, which can cause serious breathing problems, but there is no proper treatment, has been suggested. Korean researchers have identified for the first ...

Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced positive results of the COMPANION study ...

MILAN ― Numerous unresolved questions surround progressive pulmonary fibrosis (PPF) treatment, according to Elisabeth Bendstrup, MD, PhD, a researcher and clinical professor in the Department of ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted breakthrough therapy designation to an oral lysophosphatidic acid receptor 1 antagonist that ...

In a recent study published in The Lancet Respiratory Medicine, a team of researchers compared the efficacy of the controlled release of low-dose morphine as an antitussive treatment against that of a ...